AIMS: To determine the significance of p63 protein expression in the development and progression of lung adenocarcinoma. METHODS AND RESULTS: The expression of p63 was immunohistochemically investigated in 92 cases of lung adenocarcinoma with a maximum diameter of 30 mm or less. p63 expression was observed not only in the nuclei (46/92 cases, 50%), but also in the cytoplasm of neoplastic cells (47/92, 51%). Nuclear localization of p63 was correlated with nuclear accumulation of p53 (P=0.0120), whereas the presence of nuclear p63 had no apparent effect on patient survival. Cytoplasmic localization of p63 was found to be correlated with shorter survival periods by univariate and multivariate analyses (P=0.0486 and P=0.0488, respectively) and the relation was independent of clinicopathological factors. Cytoplasmic localization of p63 was further confirmed by immunoblots of the cytoplasmic fraction of HLC-1, a lung adenocarcinoma cell line which predominately expressed DeltaNp63alpha transcript relative to TAp63 transcript by quantitative reverse transcriptase-polymerase chain reaction. CONCLUSIONS: Cytoplasmic expression of p63 is an adverse prognostic factor in patients with adenocarcinoma of the lung.
AIMS: To determine the significance of p63 protein expression in the development and progression of lung adenocarcinoma. METHODS AND RESULTS: The expression of p63 was immunohistochemically investigated in 92 cases of lung adenocarcinoma with a maximum diameter of 30 mm or less. p63 expression was observed not only in the nuclei (46/92 cases, 50%), but also in the cytoplasm of neoplastic cells (47/92, 51%). Nuclear localization of p63 was correlated with nuclear accumulation of p53 (P=0.0120), whereas the presence of nuclear p63 had no apparent effect on patient survival. Cytoplasmic localization of p63 was found to be correlated with shorter survival periods by univariate and multivariate analyses (P=0.0486 and P=0.0488, respectively) and the relation was independent of clinicopathological factors. Cytoplasmic localization of p63 was further confirmed by immunoblots of the cytoplasmic fraction of HLC-1, a lung adenocarcinoma cell line which predominately expressed DeltaNp63alpha transcript relative to TAp63 transcript by quantitative reverse transcriptase-polymerase chain reaction. CONCLUSIONS: Cytoplasmic expression of p63 is an adverse prognostic factor in patients with adenocarcinoma of the lung.
Authors: Natalya Frolova; Mick D Edmonds; Thomas M Bodenstine; Robert Seitz; Martin R Johnson; Rui Feng; Danny R Welch; Andra R Frost Journal: Tumour Biol Date: 2009-07-16
Authors: Yi-Hsuan Hsiao; Yan A Su; Horng-Der Tsai; Jeffrey T Mason; Ming-Chih Chou; Yan-gao Man Journal: Int J Biol Sci Date: 2010-08-08 Impact factor: 6.580
Authors: Preet K Dhillon; Marc Barry; Meir J Stampfer; Sven Perner; Michelangelo Fiorentino; Alessandro Fornari; Jing Ma; Julia Fleet; Tobias Kurth; Mark A Rubin; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01-20 Impact factor: 4.254
Authors: Péter Mendik; Levente Dobronyi; Ferenc Hári; Csaba Kerepesi; Leonardo Maia-Moço; Donát Buszlai; Peter Csermely; Daniel V Veres Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971
Authors: Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi Journal: J Exp Med Date: 2013-02-18 Impact factor: 14.307